2018 Q1 Form 10-Q Financial Statement
#000156459018013008 Filed on May 10, 2018
Income Statement
| Concept | 2018 Q1 | 2017 Q1 |
|---|---|---|
| Revenue | $66.52M | $0.00 |
| YoY Change | ||
| Cost Of Revenue | $6.383M | |
| YoY Change | ||
| Gross Profit | $60.13M | |
| YoY Change | ||
| Gross Profit Margin | 90.4% | |
| Selling, General & Admin | $36.60M | $18.40M |
| YoY Change | 98.92% | 66.67% |
| % of Gross Profit | 60.87% | |
| Research & Development | $46.93M | $54.80M |
| YoY Change | -14.36% | -8.98% |
| % of Gross Profit | 78.04% | |
| Depreciation & Amortization | $1.340M | $280.0K |
| YoY Change | 378.57% | 33.33% |
| % of Gross Profit | 2.23% | |
| Operating Expenses | $36.60M | $54.80M |
| YoY Change | -33.21% | -23.08% |
| Operating Profit | $23.53M | |
| YoY Change | ||
| Interest Expense | $1.079M | $350.0K |
| YoY Change | 208.29% | 25.0% |
| % of Operating Profit | 4.59% | |
| Other Income/Expense, Net | -$951.0K | -$10.00K |
| YoY Change | 9410.0% | -103.65% |
| Pretax Income | -$24.35M | -$72.87M |
| YoY Change | -66.58% | 2.68% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$24.35M | -$72.87M |
| YoY Change | -66.59% | 2.67% |
| Net Earnings / Revenue | -36.6% | |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$645.9K | -$1.973M |
| COMMON SHARES | ||
| Basic Shares Outstanding | 36.95M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2018 Q1 | 2017 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $78.60M | $194.0M |
| YoY Change | -59.48% | 7.06% |
| Cash & Equivalents | $82.87M | $109.4M |
| Short-Term Investments | $88.90M | |
| Other Short-Term Assets | $13.60M | $10.70M |
| YoY Change | 27.1% | 32.1% |
| Inventory | $2.742M | |
| Prepaid Expenses | ||
| Receivables | $16.31M | |
| Other Receivables | $0.00 | |
| Total Short-Term Assets | $111.2M | $204.6M |
| YoY Change | -45.65% | 8.05% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $4.300M | $5.000M |
| YoY Change | -14.0% | 125.33% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $6.800M | $7.000M |
| YoY Change | -2.86% | -48.53% |
| Total Long-Term Assets | $58.44M | $12.00M |
| YoY Change | 386.99% | -24.13% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $111.2M | $204.6M |
| Total Long-Term Assets | $58.44M | $12.00M |
| Total Assets | $169.6M | $216.6M |
| YoY Change | -21.68% | 5.57% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $23.56M | $24.00M |
| YoY Change | -1.83% | -3.37% |
| Accrued Expenses | $34.56M | $19.80M |
| YoY Change | 74.54% | 40.74% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $58.12M | $43.70M |
| YoY Change | 32.99% | 12.32% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $48.60M | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $5.500M | $5.500M |
| YoY Change | 0.0% | 323.08% |
| Total Long-Term Liabilities | $54.10M | $5.500M |
| YoY Change | 883.64% | 323.08% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $58.12M | $43.70M |
| Total Long-Term Liabilities | $54.10M | $5.500M |
| Total Liabilities | $112.2M | $49.20M |
| YoY Change | 128.05% | 22.29% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | ||
| YoY Change | ||
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $57.46M | $167.4M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $169.6M | $216.6M |
| YoY Change | -21.7% | 5.56% |
Cashflow Statement
| Concept | 2018 Q1 | 2017 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$24.35M | -$72.87M |
| YoY Change | -66.59% | 2.67% |
| Depreciation, Depletion And Amortization | $1.340M | $280.0K |
| YoY Change | 378.57% | 33.33% |
| Cash From Operating Activities | -$6.253M | -$36.04M |
| YoY Change | -82.65% | 2.88% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $40.00K | $124.0K |
| YoY Change | -67.74% | 181.82% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $0.00 | -$53.95M |
| YoY Change | -100.0% | -166.2% |
| Cash From Investing Activities | -$40.00K | -$54.07M |
| YoY Change | -99.93% | -166.38% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 3.147M | 710.0K |
| YoY Change | 343.24% | 222.73% |
| NET CHANGE | ||
| Cash From Operating Activities | -6.253M | -36.04M |
| Cash From Investing Activities | -40.00K | -54.07M |
| Cash From Financing Activities | 3.147M | 710.0K |
| Net Change In Cash | -3.146M | -89.40M |
| YoY Change | -96.48% | -291.64% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$6.253M | -$36.04M |
| Capital Expenditures | $40.00K | $124.0K |
| Free Cash Flow | -$6.293M | -$36.16M |
| YoY Change | -82.6% | 3.11% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
16309000 | |
| CY2018Q1 | us-gaap |
Inventory Net
InventoryNet
|
2742000 | |
| CY2018Q1 | us-gaap |
Long Term Debt
LongTermDebt
|
48556000 | |
| CY2018Q1 | us-gaap |
Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
|
47368000 | |
| CY2018Q1 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
4317000 | |
| CY2018Q1 | us-gaap |
Assets
Assets
|
169639000 | |
| CY2018Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
23560000 | |
| CY2018Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
34558000 | |
| CY2018Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
58118000 | |
| CY2018Q1 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
5509000 | |
| CY2018Q1 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
36016000 | |
| CY2018Q1 | us-gaap |
Licenses Revenue
LicensesRevenue
|
30500000 | |
| CY2018Q1 | us-gaap |
Revenues
Revenues
|
66516000 | |
| CY2018Q1 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
6383000 | |
| CY2018Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
36602000 | |
| CY2017Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
54801000 | |
| CY2018Q1 | us-gaap |
Interest Expense
InterestExpense
|
1079000 | |
| CY2018Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-24345000 | |
| CY2018Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-24345000 | |
| CY2017Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-72865000 | |
| CY2018Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.65 | |
| CY2017Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.97 | |
| CY2018Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
37699024 | |
| CY2017Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
36931167 | |
| CY2017Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-37000 | |
| CY2018Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-24345000 | |
| CY2017Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-72902000 | |
| CY2018Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
25352000 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
3147000 | |
| CY2018Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1341000 | |
| CY2017Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
277000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
25352000 | |
| CY2017Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
29764000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
6639000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
713000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
1045000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
-516000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-4217000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
3935000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
3910000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
2334000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
|
-103000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
|
3000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-6253000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-36042000 | |
| CY2018Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
40000 | |
| CY2017Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
124000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-40000 | |
| CY2018Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
3147000 | |
| CY2017Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
706000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
3147000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
706000 | |
| CY2018Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-3146000 | |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-89409000 | |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
86015000 | |
| CY2016Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
198811000 | |
| CY2018Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
82869000 | |
| CY2017Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
109402000 | |
| CY2018Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
85000 | |
| CY2018Q1 | pbyi |
Receivables Related To Stock Option Exercises
ReceivablesRelatedToStockOptionExercises
|
68000 | |
| CY2018Q1 | us-gaap |
Interest Paid
InterestPaid
|
989000 | |
| CY2018Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates: </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the balance sheet, and reported amounts of expenses for the period presented. Accordingly, actual results could differ from those estimates. </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant estimates include estimates for variable consideration for which reserves were established. These estimates are included in the calculation of net revenues and include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the Company’s sale of its products. </p></div> | |
| CY2018Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Risk: </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents and accounts receivable. The Company’s cash and cash equivalents and restricted cash in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at March 31, 2018, were approximately $83.1 million. The Company does not believe it is exposed to any significant credit risk due to the quality nature of the financial instruments in which the money is held. Pursuant to the Company’s internal investment policy, investments must be rated A-1/P-1 or better by Standard and Poor’s Rating Service and Moody’s Investors Service at the time of purchase. </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sells its products in the United States primarily through specialty pharmacies and specialty distributors. Therefore, wholesale distributors and large pharmacy chains account for a large portion of its trade receivables and net product revenues. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for doubtful accounts primarily based on the credit worthiness of our customers, historical payment patterns, aging of receivable balances and general economic conditions.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s success depends on its ability to successfully commercialize NERLYNX. The Company currently has a single product with limited commercial sales experience, which makes it difficult to evaluate its current business, predict its future prospects and forecast financial performance and growth. The Company has invested a significant portion of its efforts and financial resources in the development and commercialization of the lead product, NERLYNX, which was approved by the FDA for the extended adjuvant treatment of early stage, HER2-positive breast cancer in the United States on July 17, 2017, and expects NERLYNX to constitute the vast majority of product revenue for the foreseeable future. The Company’s success depends on its ability to effectively commercialize NERLYNX. </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Company relies exclusively on third parties to formulate and manufacture NERLYNX and its drug candidates. The commercialization of NERLYNX and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those third parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company has no experience in drug formulation or manufacturing and does not intend to establish its own manufacturing facilities. The Company lacks the resources and expertise to formulate or manufacture NERLYNX and other drug candidates. While the drug candidates were being developed by Pfizer, both the drug substance and drug product were manufactured by third-party contractors. The Company is using the same third-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and the commercialization of NERLYNX. If the Company is unable to continue its relationships with one or more of these third-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on one or more third-party contractors to manufacture the commercial supply of drugs.</font></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p></div> | |
| CY2018Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1000000 | |
| CY2018Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
|
2900000 | |
| CY2018Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
3900000 | |
| CY2018Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
3900000 | |
| CY2018Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
3900000 | |
| CY2018Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
3900000 | |
| CY2018Q1 | pbyi |
Finite Lived Intangible Assets Amortization Expense Year Six
FiniteLivedIntangibleAssetsAmortizationExpenseYearSix
|
3900000 | |
| CY2018Q1 | pbyi |
Finite Lived Intangible Assets Amortization Expense Year Seven
FiniteLivedIntangibleAssetsAmortizationExpenseYearSeven
|
3900000 | |
| CY2018Q1 | pbyi |
Finite Lived Intangible Assets Amortization Expense Year Eight
FiniteLivedIntangibleAssetsAmortizationExpenseYearEight
|
3900000 | |
| CY2018Q1 | pbyi |
Finite Lived Intangible Assets Amortization Expense Year Nine
FiniteLivedIntangibleAssetsAmortizationExpenseYearNine
|
3900000 | |
| CY2018Q1 | pbyi |
Finite Lived Intangible Assets Amortization Expense Year Ten
FiniteLivedIntangibleAssetsAmortizationExpenseYearTen
|
3900000 | |
| CY2018Q1 | pbyi |
Finite Lived Intangible Assets Amortization Expense Year Eleven
FiniteLivedIntangibleAssetsAmortizationExpenseYearEleven
|
3900000 | |
| CY2018Q1 | pbyi |
Finite Lived Intangible Assets Amortization Expense Year Twelve
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwelve
|
3900000 | |
| CY2018Q1 | pbyi |
Finite Lived Intangible Assets Amortization Expense Year Thirteen
FiniteLivedIntangibleAssetsAmortizationExpenseYearThirteen
|
1000000 | |
| CY2018Q1 | pbyi |
Incremental Costs Expenses
IncrementalCostsExpenses
|
0 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
78552000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
81698000 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
78552000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
81698000 | |
| CY2018Q1 | pbyi |
Cash And Cash Equivalents And Restricted Cash In Excess Of Insured Limits
CashAndCashEquivalentsAndRestrictedCashInExcessOfInsuredLimits
|
83100000 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.35 | |
| CY2018Q1 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
| CY2018Q1 | pbyi |
Tax Cuts And Jobs Act Of2017 Change In Tax Rate Deferred Tax Assets Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetsIncomeTaxExpenseBenefit
|
141100000 | |
| CY2018Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2018Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9891878 | |
| CY2017Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9549076 | |
| CY2017Q4 | us-gaap |
Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
|
14986000 | |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
8533000 | |
| CY2017Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
4063000 | |
| CY2018Q1 | us-gaap |
Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
|
50000000 | |
| CY2018Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
2632000 | |
| CY2018Q1 | pbyi |
Accrued Development Costs
AccruedDevelopmentCosts
|
7493000 | |
| CY2017Q4 | pbyi |
Accrued Development Costs
AccruedDevelopmentCosts
|
8335000 | |
| CY2018Q1 | pbyi |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
4513000 | |
| CY2017Q4 | pbyi |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
3438000 | |
| CY2018Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
3136000 | |
| CY2017Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
2046000 | |
| CY2018Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
4359000 | |
| CY2017Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2797000 | |
| CY2018Q1 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
2478000 | |
| CY2017Q4 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
3376000 | |
| CY2018Q1 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
5357000 | |
| CY2017Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
3922000 | |
| CY2018Q1 | pbyi |
Accrued Variable Consideration Current
AccruedVariableConsiderationCurrent
|
3922000 | |
| CY2017Q4 | pbyi |
Accrued Variable Consideration Current
AccruedVariableConsiderationCurrent
|
1425000 | |
| CY2018Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
3300000 | |
| CY2017Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
5309000 | |
| CY2018Q1 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
50000000 | |
| CY2018Q1 | us-gaap |
Deferred Finance Costs Net
DeferredFinanceCostsNet
|
1444000 | |
| CY2018Q1 | us-gaap |
Debt Instrument Maturity Date
DebtInstrumentMaturityDate
|
2022-10-31 | |
| CY2018Q1 | pbyi |
Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
|
25352000 | |
| CY2017Q1 | pbyi |
Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
|
29764000 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
87.91 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
73.40 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
54.33 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
38.11 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
145.51 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
88.00 | |
| CY2018Q1 | pbyi |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice
|
55.60 | |
| CY2018Q1 | pbyi |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
|
P9Y9M18D | |
| CY2018Q1 | pbyi |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
|
P8Y7M6D | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
220060000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
2256000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
100125000 | |
| CY2018Q1 | pbyi |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedIntrinsicValue
|
27237000 | |
| CY2017Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
1788436 | |
| CY2018Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
|
419025 | |
| CY2018Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
|
80604 | |
| CY2017Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
|
33.37 | |
| CY2018Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
|
38.79 | |
| CY2018Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
|
32.66 | |
| CY2016Q2 | pbyi |
Number Of Stockholders Derivative Lawsuits
NumberOfStockholdersDerivativeLawsuits
|
2 |
